Obesity
Webinar: Enhancing clinical trials in obesity by integrating COAs and DHTs
The development landscape for overweight and obesity therapies is rapidly evolving, shaped by regulatory guidance and advances in how therapeutic value is measured. This webinar will explore how Clinical Outcome Assessments and digital health technologies are reshaping obesity trials through patient-centered approaches.
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=310&h=310&itok=Wa05gqKN "obesity_scan_icons"){kind=icon}
Survey report
How today’s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=310&h=310&itok=dW5Jhe6R "obesity scan person"){kind=icon}
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future.
Obesity blogs and media contributions
-
Media article: Unlocking the potential of GLP-1 based therapies with RWE
A recent ICON survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
Media article: Cardiovascular outcomes trials revisited – methodological enhancements for greater clinical relevance.
ICON experts, Pierre Martineau and Adrienne Stoudenmire, share key considerations for successful CVOTs including study design, data strategy and technology in this new article.
-
Media article: Embracing proactive multi-indication development for metabolic therapies
In this article, ICON expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
-
Media article: Strategic Commercialisation of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle Value
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Media article: Survey of Obesity Developers Suggests Multi-Indication Approaches are Vital but Demanding
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An ICON survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
Media article: Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss
New research from Symphony Health, an ICON plc company, featured in The American Journal of Managed Care (AMJC), highlights ongoing challenges in patient access to GLP-1 therapies for weight loss.
-
Media article: Tackling the next frontier in metabolic trials: A Q&A with ICON experts
In this article, ICON experts explore strategies to help sponsors navigate the evolving obesity research landscape, highlighting the use of adaptive designs, master protocols, and other innovative approaches.
-
.jpeg?crop=yes&w=545&h=286&itok=tVyU6bWe "obesity_scan_icons")
Media article: Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
.jpeg?crop=yes&w=1665&h=876&a=0,71&itok=je--xbq9 "obesity_scan_icons"){kind=icon}
Interdisciplinary expertise in obesity research services
ICON’s highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including obesity, diabetes, cardiometabolic disorders and hepatology including MASH.